COMPASS-CAT (Cancer-Associated VTE Risk)
COMPASS-CAT VTE risk score (Gerotziafas 2017): anti-hormonal/anthracycline therapy, recent diagnosis, central line, advanced stage, cardiovascular risk factors, recent hospitalization, prior VTE,…
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Anti-hormonal or anthracycline therapy
- Yes
- Cancer diagnosis ≤ 6 months ago
- Yes
Result: COMPASS-CAT 10 — high 6-month VTE risk (≥ 7).
The tool opens with these values already filled in. Replace them with your own.
What the result means
- Risk
- Dichotomized 0–6 low/intermediate vs ≥ 7 high 6-month VTE risk (≈ 2.3% vs ≈ 6.3–13.3%). A complement to Khorana for ambulatory cancer patients; a risk stratifier, not a thromboprophylaxis order.
What you enter
- Anti-hormonal or anthracycline therapy (+6)
- Cancer diagnosis ≤ 6 months ago (+4)
- Central venous catheter (+3)
- Advanced-stage cancer (+2)
- Cardiovascular risk factors (+5)
- Recent hospitalization for acute medical illness (+5)
- Personal history of VTE (+1)
- Platelet count ≥ 350 ×10⁹/L (+2)
How this is calculated
- Points
- Anti-hormonal/anthracycline +6, diagnosis ≤ 6 mo +4, central venous catheter +3, advanced stage +2, CV risk factors +5, recent hospitalization +5, prior VTE +1, platelets ≥ 350 +2. Total 0–28.
Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-CAT study. Oncologist. 2017;22(10):1222-1231. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.